Objective: We previously demonstrated that positive allosteric modulators (PAMs) of metabotropic glutamate subtype 2 (mGlu 2 ) receptors have potential synergistic interactions with the antiseizure drug levetiracetam (LEV). The present study utilizes isobolographic analysis to evaluate the combined administration of JNJ-46356479, a selective and potent mGlu 2 PAM, with LEV as well as sodium valproate (VPA) and lamotrigine (LTG). Methods: The anticonvulsant efficacy of JNJ-46356479 was evaluated in the 6-Hz model of psychomotor seizures in mice. JNJ-46356479 was administered in combination with LEV using 3 fixed dose-ratio treatment groups in the mouse 6-Hz (44-mA) seizure test. The combination of JNJ-46356479 with LEV was also evaluated in the mouse corneal kindling model. The potential interactions of JNJ-46356479 with the antiseizure drugs VPA and LTG were also evaluated using fixed dose-ratio combinations. Plasma levels were obtained for analysis of potential pharmacokinetic interactions for each combination studied in the mouse 6-Hz model. Results: JNJ-46356479 was active in the 6-Hz model at both 32-mA and 44-mA stimulus intensities (median effective dose = 2.8 and 10.2 mg/kg, respectively).
polypharmacy approach to treat patients with refractory epilepsy, once it has been confirmed in clinical studies.
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| INTRODUCTION
The metabotropic glutamate receptor subtype 2 (mGlu 2 ) receptor is a potential therapeutic target in the treatment of epilepsy. Activation of mGlu 2 receptors decreases glutamate release, [1] [2] [3] and this receptor subtype is expressed presynaptically in the frontal cortex and in limbic structures. [4] [5] [6] Positive allosteric modulators (PAMs) of mGlu 2 receptors, which do not directly activate the receptor yet modulate the agonist-mediated response, have been evaluated as potential therapies for neurological diseases [7] [8] [9] [10] [11] and also represent a potentially novel treatment strategy for epilepsy. Previously, PAMs have been demonstrated to block seizures in the 6-Hz model of psychomotor seizures using both the 32-mA and 44-mA stimulus intensities. 12 The antiseizure drugs sodium valproate (VPA), lamotrigine (LTG), and levetiracetam (LEV) have been previously evaluated alone and in combination with other agents, in various seizure models. [13] [14] [15] [16] [17] [18] For example, VPA or LTG in combination with gabapentin demonstrated supra-additive effects in the maximal electroshock test. 18 LEV in combination with either carbamazepine or topiramate demonstrated supra-additive effects in the maximal electroshock test and each combination was not associated with altered plasma levels. 19 Conversely, in the same study a combination of LEV with LTG was not different from the theoretical additive effect. 19 Current therapy for patients with epilepsy often requires >1 concomitant medication, 20 and preclinical studies can be informative in determining which combinations may be beneficial. Specific combinations are best evaluated using isobolographic analysis, 21, 22 wherein each drug can individually confer dose-dependent efficacy and various dose-ratio combinations are used (ie, drugs are administered as a proportion of median effective dose [ED 50 ]). Supra-additive or synergistic interactions occur when the combination yields greater potency than would be predicted for a simple additive effect (the opposite is true for subadditive or antagonistic interactions). Furthermore, evaluation of each drug combination should also include collection of plasma samples to verify whether pharmacokinetic interactions are contributing to the subor supra-additive effects observed. Using this approach, we extend the preclinical profile of mGlu 2 PAMs by analysis of the potent and selective mGlu 2 PAM JNJ-46356479 23 in 6-Hz and corneal kindling models, alone or in combination with the antiseizure drugs VPA, LTG, and LEV.
| MATERIALS AND METHODS

| Compound preparation
A 40% hydroxypropyl-beta-cyclodextrin (HPbCD; Sigma, St. Louis, MO, USA) preparation was used for preparation of stock solutions of JNJ-46356479. The compound was stirred on a heated plate (~70°C) until dissolution, and pH was adjusted to 4. Sterile water was added to the final solution so that the final concentration of the dosing solution also contained 20% HPbCD. Typically, dosing solutions were prepared fresh on the day of testing. Occasionally, dosing solutions from a previous preparation within a study were used (≤3 days old, stored at 4°C, and warmed to room temperature prior to dosing). All dosing solutions were mixed thoroughly prior to administration. The vehicle (VEH) solution for JNJ-46356479 was 20% HPbCD. VPA (Sigma), LEV (Sigma), and LTG (AK
Key Points
• PAMs of the mGlu 2 receptor demonstrate anticonvulsant efficacy in the mouse 6-Hz and corneal kindling models
• The mGlu 2 PAM JNJ-46356479 administered in combination with LEV is substantially more potent than predicted for a simple additive effect
• The synergism of JNJ-46356479 with LEV was not associated with changes in plasma levels in comparison to either compound administered alone, suggesting this combined efficacy is not due to pharmacokinetic interactions
• The synergism of JNJ-46356479 with LEV seems specific, as it did not extend to other antiseizure drugs; that is, combined administration with either VPA or LTG yielded only additive effects Scientific, Union City, CA, USA) were prepared using a 0.5% methylcellulose (Sigma) preparation.
| Animals and compound administration
Adult male CF-1 mice (25-40 g), used for the 6-Hz and corneal kindling assays, were obtained from Charles River (Kingston, NY, USA). Animals were allowed free access to food and water, except during testing periods. After delivery, animals were allowed sufficient time to acclimate to housing conditions prior to testing. All mice were housed in plastic cages in rooms with controlled humidity, ventilation, and lighting (12 hours on, 12 hours off). The animals were housed and fed in a manner consistent with the recommendations in the Guide for Care and Use of Laboratory Animals (National Research Council), and in accordance with guidelines set by the institutional animal care and use committee of the University of Utah. Test compounds were administered using an optimal fluid volume to body fluid ratio. Test compounds were administered to mice in a volume of 0.01 mL/g body weight.
JNJ-46356479 was administered by subcutaneous (SC) injection. VPA, LEV, and LTG were administered by intraperitoneal (IP) injection. Each compound was administered at its previously determined time-to-peak effect prior to testing.
| Six-hertz psychomotor seizure test
Focal seizures that secondarily generalized were induced in mice via corneal stimulation using a Grass Instrument Co.
(West Warwick, RI, USA) S48 stimulator (6 Hz, 0.2-millisecond rectangular pulse, 3-second duration 14, 24 ). Mice were tested at either 32-mA or 44-mA stimulus intensity. Prior to stimulation, drops of 0.5% tetracaine were applied to each eye. The seizures that arise from corneal stimulation in this assay are characterized by a minimal clonic phase followed by stereotyped automatistic behaviors including stun, forelimb clonus, twitching of the vibrissae, and Straub-tail. If any of these behaviors occurred during a 1-minute observation period following stimulation, the animal was considered as having demonstrated a seizure. Animals not displaying any of the behaviors noted above were considered "protected." Although experiments were not conducted by a blinded reviewer, a second reviewer was present to verify behavioral seizure observations. Separate studies were conducted to evaluate dose-response relationships for each compound using either 32-mA or 44-mA stimulus intensity. Dose-response studies for JNJ-46356479 included 8-16 per group (n = 52 for 32-mA dose-response study and n = 32 for 44-mA dose-response study). VEH treatment groups for 32-mA and 44-mA studies were also included (n = 8 per group). For the VPA and LTG doseresponse studies, group sizes were 8 per group (n = 24 total for each drug). Initial time-course studies were conducted to determine pretreatment times for each compound. Pretreatment times were 0.25 hours (VPA), 0.5 hours (JNJ-46356479), and 1 hour (LEV and LTG). ED 50 and 95% confidence interval (CI) were calculated using Probit analysis. For combination studies, compounds were administered using the same pretreatment time and route used for single administration studies.
| Corneal kindling
Mice were stimulated for 3 seconds, using a 3-mA, 60-Hz stimulus from corneal electrodes. 13 
| Rotarod test for motor impairment
Testing in the rotarod was conducted in tandem with 6-Hz or corneal kindling stimulation to verify whether doses administered produced substantial motor impairment. Evaluation in the rotarod assay was conducted immediately prior to 6-Hz or corneal kindling testing. When mice are placed on a 1-inch knurled rod rotating at a speed of 6 rpm, the animals can maintain equilibrium for long periods of time. Motor impairment was assessed by determining whether mice remained on the rotarod during a 1-minute observation period; that is, 3 falls during a 1-minute period was considered a rotarod failure.
| Combination studies
Isobolographic studies were conducted for the combined administration of JNJ-46356479 with LEV in the 6-Hz (44-mA) assay. Studies were conducted according to previously described methods. 19 Isobolographic studies were also employed for JNJ-46356479 and either VPA or LTG, using 1:1 dose ratios. Each treatment group included 8 mice, with n = 24 total for each of the 1:1 dose-ratio studies for VPA and LTG.
| Serum collection for analysis of plasma drug levels
In various tests, animals were sacrificed following testing, and trunk blood was collected for quantification of drug levels. Immediately after testing, animals were decapitated and trunk blood was collected into a BD Vacutainer tube (Becton, Dickinson, and Co., Franklin Lakes, NJ, USA) containing K2EDTA and chilled on ice until centrifugation. Following centrifugation (13 000-18 000 rpm, 5-7 minutes), the plasma was removed and transferred to a labeled microcentrifuge tube and stored at À80°C until testing. The frozen sample was placed in a labeled centrifuge tube and stored at À80°C until analysis of samples. Compound levels were detected using liquid chromatography/tandem mass spectrometry (API-4000 LC/MS/MS system, Applied Biosystems, Cheshire, UK).
| Statistical analysis
Seizure protection and rotarod motor impairment data are presented as n protected/n tested and n with motor impairment/n tested, respectively. A Fisher's exact test was used to compare seizure efficacy or motor impairment values for specific treatment groups with VEH-treated animals. For dose-response analyses, ED 50 (and 95% CI) values were calculated using a Probit analysis wherein 3-4 treatment groups (n = 8 per group) were used in the calculation. Plasma levels are presented as means AE SEM and were compared using a Student t test or 1-way analysis of variance. For isobolographic studies, ED 50,exp values for each fixed dose-ratio combination were compared to ED 50,add values using a Student t test. The dose ratio was determined to be supra-additive (synergistic) if the experimentally determined ED 50 value was significantly lower than the theoretical ED 50 .
3 | RESULTS
| Anticonvulsant screening in the 6-Hz model
The dose-dependent ability of JNJ-46356479 to block 6-Hz seizures was evaluated following SC administration in the 6-Hz assay, using both 32-mA and 44-mA stimulus intensities. The time of peak effect was previously determined to be 0.5 hour following SC administration (data not shown). JNJ-46356479 was administered at several doses (0.5-20 mg/kg) followed by testing in the rotarod assay and 6-Hz assay (see Table 1 ). The compound was well-tolerated at doses up to 20 mg/kg; that is, minimal motor impairment (1/8 mice at 32 and 44 mA) was observed at the highest dose (20 mg/kg) tested (Table 1) . Using the 32-mA stimulus intensity, the ED 50 (95% CI) was determined to be 2.8 mg/kg (1.3-4.3). Similarly, using the 44-mA stimulus intensity, the ED 50 (95% CI) was determined to be 10.2 mg/kg (3.1-12.4). Receptor occupancy studies in rats suggest that 80%-100% receptor occupancy is reached at the ED 50 doses tested (data not shown). ). Table 2 shows the dose-response relationship for various dose-ratio combinations of JNJ-46356479 and LEV in the isobolographic study. Figure 1 shows the isobolographic analysis for the combination of JNJ-46356479 with LEV in the 6-Hz (44-mA) assay. ED 50,exp values determined were significantly lower, in each of the 3 dose-ratio combinations, than ED 50,add values, and this synergistic interaction occurred without producing any measurable motor impairment.
Plasma levels of LEV and JNJ-46356479, obtained from mice used in the isobolographic study, are presented in Figure 2A ,B, respectively. Equivalent doses (ie, from separate dose-ratio treatment paradigms) were evaluated for similarity in plasma drug levels. For example, LEV 22.6 mg/kg was tested for both the 1:1 and 1:3 paradigms, and produced similar plasma levels.
Similarly, LEV 45.3 mg/kg plasma levels were similar for both the 1:1 and 1:3 groups. For JNJ-46356479, 0.6 mg/kg tested in the 1:1 and 3:1 dose-ratio groups produced similar plasma levels. Doses of 1.3 mg/kg (tested in 1:1 and 3:1 paradigms) and 2.6 mg/kg (tested in 1:1 and 3:1 paradigms) of JNJ-46356479 also produced similar plasma levels. In addition, plasma levels of LEV, when administered alone, showed similar plasma concentrations for comparable doses (compare Figure 2 with Table S1 ).
| Evaluation of the combination of JNJ-46356479 and LEV in the corneal kindling model
JNJ-46356479 was also evaluated in combination with LEV for efficacy in the corneal kindling model. As shown in Table 3 , LEV 3 mg/kg was moderately effective in corneal kindling (38% protected). Similarly, JNJ-46356479 at doses of 20 and 30 mg/kg produced low levels of efficacy (31% and 25% protected, respectively). In combination, LEV 3 mg/kg + JNJ-46356479 20 mg/kg was partially effective (70% protected), whereas a combination of LEV 3 mg/kg + JNJ-46356479 30 mg/kg was observed to be fully efficacious (100% protected) and significantly effective (vs VEH and LEV 3 mg/kg). There were no significant signs of motor toxicity noted following treatment with LEV or JNJ-46356479 alone or in combination in corneal kindled mice. The antiseizure drugs VPA and LTG were also evaluated in the 6-Hz model, using the 44-mA stimulus intensity. VPA was administered, IP, at doses of 150, 250, and 400 mg/kg, followed by testing 0.25 hour following treatment (the time-to-peak effect was previously determined; see Table 4 ). The ED 50 (95% CI) for VPA in the 44-mA assay was determined to be 290 mg/kg (196-566). Motor impairment (4 of 8 mice tested) was observed at a dose of 400 mg/kg. In addition, plasma levels of VPA showed a dose-proportional increase at the doses tested (see Table 4 ). LTG was evaluated at doses of 10, 25, and 50 mg/kg (IP) followed by testing 1 hour later. As we could not achieve full protection using LTG at doses that would not produce significant motor impairment, 28 the ED 50 value reported for LTG in Table 4 is estimated and a dose of 50 mg/kg was used for combination studies. Furthermore, no significant motor impairment was observed following LTG administration at the doses used. Plasma concentrations for LTG were found to be doseproportional (see Table 4 ). VPA was evaluated in combination with JNJ-46356479 in the 6-Hz 44-mA assay using a 1:1 ED 50 dose-proportionality design wherein equivalent fractions of ED 50 doses were administered in combination (see Table 4 ). Doses of 10 and 300 mg/kg for JNJ-43656479 and VPA, respectively, which are equivalent to ED 50 doses for each compound when administered alone, were fully efficacious when administered together. Furthermore, the combination of one-half of ED 50 doses, that is, JNJ-46356479 5 mg/ kg + VPA 150 mg/kg, was also highly effective (Table 4) . Finally, at dose combinations representing one-fourth of their respective ED 50 values, the combination of JNJ-46356479 2.5 mg/kg and VPA 75 mg/kg produced 25% efficacy (see Table 4 ). However, no significant difference was observed when ED 50,add and ED 50,exp were compared and therefore this combination is not deemed to be synergistic. Plasma concentrations for JNJ-46356479 and VPA increased proportionally to increases in dose. Plasma concentrations for VPA, 150 mg/kg, were similar in this combination to those obtained in the dose-response study (see Table 4 ).
Following these studies, a minimally effective dose of JNJ-46356479 (2.5 mg/kg, ineffective when administered alone, see Table 1 ) was coadministered with VPA at various doses to evaluate whether JNJ-46356479 produced a shift in the potency of VPA. The ED 50 (95% CI) for VPA was 89 mg/kg (56-132), which is~3-fold lower than VPA administered alone (see Table 4 ). Plasma values for JNJ-46356479 2.5 mg/kg were similar for all dose combinations evaluated, whereas VPA plasma concentrations increased in a manner proportional to dose. Plasma concentrations for VPA, 150 mg/kg, were similar in this combination to those obtained in the dose-response study (see Table 4 ).
An LTG dose of 50 mg/kg produced minimal motor impairment (12.5%) and submaximal efficacy (62.5% protection), and was used as an approximate ED 50 dose in combination with JNJ-46356479 in the 6-Hz 44-mA assay. The purpose of this study was to determine whether the combination of JNJ-46356479 would improve the efficacy of LTG without a concomitant increase in motor impairment. As the dose of 50 mg/kg used was an approximate ED 50 value, the 1:1 dose-ratio combination is an estimate. Doses included in this study are shown in Table 4 . The combination of JNJ-46356479 10 mg/kg (similar to ED 50 for this compound shown in Table 1 ) and LTG 50 mg/kg (approximate ED 50 ) was fully efficacious. This dose combination also produced moderate motor impairment. When these doses were halved, JNJ-43656479 5 mg/kg + LTG 25 mg/kg was also highly effective. Furthermore, at doses one-fourth of the approximate ED 50 values for each compound, the combination of JNJ-46356479 2.5 mg/kg and LTG 12.5 mg/kg was not effective. No significant difference was observed when ED 50,add and ED 50,exp were compared. JNJ-46356479 plasma levels show a dose-proportional increase similar to the plasma levels observed for this compound in combination with VPA (see Table 4 ). Conversely, plasma levels for LTG were notably lower at doses of 25 and 50 mg/kg when coadministered with JNJ-46356479 (see Table 4 ), and this difference was significant for LTG 50 mg/kg.
| DISCUSSION
To confirm and extend the evaluation of positive pharmacodynamic interactions between mGlu 2 PAMs and LEV, 12 JNJ-46356479 was evaluated with LEV in several fixeddose combinations in an isobolographic analysis. The observed potency for this combination suggests a strong synergistic effect without evidence of pharmacokinetic interactions and without worsening of tolerability as measured by rotarod performance. To examine whether the observed synergy is specific to the 6-Hz 44-mA assay, we evaluated the effect of JNJ-46356479 alone and in combination with LEV in the mouse corneal kindling model. The combination of JNJ-46356479 30 mg/kg with LEV 3 mg/ kg prevented both generalized and focal seizures and was more effective than would be predicted for an additive effect. To determine whether this synergism extended to other antiseizure drugs, JNJ-46356479 was evaluated in combination with VPA and LTG. Despite an increase in potency of VPA in combination with mGlu 2 PAM (threefold), this shift is notably lower than that observed for LEV in combination with mGlu 2 PAMs. 12 Although the combination of LTG and JNJ-46356479 only showed an additive effect, it is noteworthy that in the presence of JNJ-46356479, LTG plasma levels were reduced significantly but still yielded a high level of protection (75%). Additional studies might be necessary to fully understand this interaction. The mGlu 2 PAM JNJ-46356479 is potently active in the 6-Hz assay at both 32-mA and 44-mA stimulus intensities. As previously noted, many established antiseizure drugs lose potency at higher stimulus intensities (eg, 44 mA).
14 It is noteworthy that although JNJ-46356479 was effective at the 44-mA stimulus intensity, with 3.6-fold lower potency than at the 32-mA stimulus intensity, efficacy was observed at doses that did not produce motor impairment in the rotarod assay. Thus, in addition to a unique mechanism of action that is distinct from currently available therapies for epilepsy, the mGlu 2 PAMs may also present a unique preclinical pharmacologic profile, with efficacy at the more pharmacoresistant 44-mA stimulus intensity without evidence of concomitant motor impairment. mGlu 2 receptors can reduce excess glutamate by modulating synaptic release, 29, 30 and thereby activation of these receptors can potentially reduce seizure activity. Further, mGlu 2 receptors are located perisynaptically 31, 32 as well as presynaptically, 6, 33 and under conditions of excess glutamate release, mGlu 2 can therefore play an influential role in reducing the probability of neurotransmitter release. LEV modulates activity of synaptic vesicle protein 2A, regulating synaptic release and thereby reducing neurotransmitter release probability. 34, 35 Therefore, although the mechanism of action of mGlu 2 PAMs and LEV are different, they share a common presynaptic regulation of glutamate neurotransmitter release and this combined effect may produce a greatly enhanced antiseizure effect greater than either agent administered alone.
Of critical importance to the interpretation of the supraadditive effects observed for the mGlu 2 PAM-LEV combination is the observation that plasma levels were similar for equivalent doses regardless of which fixed dose-ratio combination they were associated with. For example, a dose of 22.6 mg/kg for LEV, which is well below the therapeutic dose range for LEV alone in the 6-Hz 44-mA assay, was tested in both 1:1 and 1:3 paradigms and produced similar plasma levels. Similarly, a dose of 1.3 mg/kg of JNJ-46356479 was tested in 1:1 and 3:1 treatment paradigms and produced similar plasma levels. Therefore, plasma concentration analysis suggests that there is not likely a pharmacokinetic interaction between JNJ-46356479 and LEV that is contributing greater than expected plasma levels and thereby driving the supra-additive effect. However, it is noteworthy that plasma samples used were collected following acute administration and future analysis of this interaction should include additional in vitro and in vivo analysis as well as samples collected following chronic or subchronic administration.
Initially, JNJ-46356479 was evaluated at a dose of 20 mg/kg in the mouse corneal kindling model, which was highly efficacious in the mouse 6-Hz 44-mA model. As this dose was only~30% effective, a higher dose (30 mg/ kg) was also evaluated. Notably, efficacy in the mouse 6-Hz and corneal kindling models are not always similar, and may vary dramatically for various compounds. 13 As our primary aim was to confirm the positive pharmacodynamic interaction of the mGlu 2 PAM/LEV combination in a second seizure model, we did not establish the full dose response of JNJ-46356479. In the corneal kindling model, treatment at moderately effective doses (ie, 40% efficacy or lower) of either JNJ-46356479 or LEV were used in combination and demonstrate a potential for positive pharmacodynamic effects in this model. Notably, the dose combination of 30 mg/kg JNJ-46356479 and 3 mg/kg LEV produced full efficacy where lower efficacy would have been predicted. Despite this observation, a more definitive isobolographic analysis in the corneal kindling model would be necessary to better define this potential interaction. LEV demonstrates greater potency in the corneal kindling model than in the 6-Hz assay, 13 and this may play an important role in the nature of the interaction between mGlu 2 PAMs and LEV. For example, LEV was partially effective at a dose of 3 mg/kg in the corneal kindling assay, which is >100-fold more potent than observed in the 6-Hz 44-mA assay. Although the rotarod test was utilized to assay for effects of individual drugs or drug combinations on motor activity, it is not known at this time whether the combination of LEV and mGlu 2 PAMs would have a notable impact on learning and memory. LEV does not significantly affect performance on the Morris Water Maze test at a therapeutically relevant dose in rats and improves object recognition in the novel object place recognition test in partially kindled mice. 36 By contrast, activation of group II mGlu receptors impairs learning and memory, which may be improved by antagonism of mGlu 2 . 37 Therefore, effects on cognition of the combination of LEV and mGlu 2 PAMs are not currently known and warrant further investigation. Efficacy of LEV in the mouse 6-Hz 44-mA model described here is notably different than that reported previously.
14 Although the reasons behind this discrepancy are unknown, LEV has shown differing ED 50 values depending on the strain and stimulator used. 38 Moreover, the potency of LEV in the mouse 6-Hz 44-mA assay, using CF-1 mice and a Grass S48 stimulator, reported by Leclercq and Kaminski is similar to those described herein. 38 It is also possible that this discrepancy may result from different manufacturers of LEV or differences in animal suppliers or colonies. JNJ-46356479 and VPA were coadministered using a 1:1 (JNJ-46356479:VPA) fixed dose-ratio combination to evaluate potential pharmacodynamic interactions for the 2 compounds. The combination of ED 50 doses for each compound was fully effective, as expected (10 mg/kg and 300 mg/kg for JNJ-46356479 and VPA, respectively) for this dose combination. However, when these doses were decreased by 50%, the combined administration retained a high level of efficacy. Using a similar treatment paradigm as previously described for LEV in combination with mGlu 2 PAMs, 12 JNJ-46356479 was administered using a minimally effective dose (ie, a dose that was ineffective when administered alone in the 6-Hz 44-mA assay) in combination with various doses of VPA to determine whether the mGlu 2 PAM shifted the potency of VPA. The threefold shift in the potency of VPA suggests a potential benefit to combined administration of these compounds, although it is worth noting that additional dose-ratio combinations may be necessary to determine whether this shift in potency is indicative of a true synergistic interaction. In addition, plasma levels for JNJ-46356479 and VPA increased in a dose-dependent manner, suggesting that the combined efficacy of this drug combination is not likely driven by altered plasma levels of either compound. LTG has been previously demonstrated to be effective in the mouse 6-Hz model, but at doses that also produce motor impairment. 28 Similarly we observed partial efficacy with LTG at a dose of 50 mg/kg, which also produced minimal motor impairment (12.5% of animals). However, this motor impairment is markedly reduced from that reported previously. 14 The potential cause of this discrepancy is unknown. Although the combination of JNJ-46356479 with LTG was highly effective using an approximated 1:1 fixed dose-ratio combination at both 100% and 50% ED 50 combinations, the lack of efficacy at lower doses (25% ED 50 combination) and no significant difference between theoretical and experimental ED 50 values for this combination suggest only an additive effect. Furthermore, plasma levels for LTG in combination were significantly lower (eg, for the 50-mg/kg dose in combination with JNJ-46356479) than those for LTG administration alone. Although the mechanism for the decreased plasma levels is not currently described, it is suggestive of a potential metabolic interaction and warrants further investigation. These studies demonstrate the therapeutic potential of the combination of LEV with mGlu 2 PAMs in treatmentresistant epilepsy. However, it is noteworthy that the experimenters in this study were not blinded to all study conditions, although a second seizure reviewer was present to validate behavioral seizure results. Therefore, one limitation of the present study is the risk of bias in interpreting study results. Despite this limitation, activity of mGlu 2 PAMs in combination with LEV in these seizure models represents a unique therapeutic opportunity that warrants additional investigation. The 6-Hz (44-mA) model is representative of an acute therapy-resistant seizure model, as mice were both drug-and seizure-naive prior to inclusion in these studies. Similarly, the corneal kindling model is representative of the network hyperexcitability that occurs in epilepsy. To verify the benefit of mGlu 2 PAMs for patients with chronic epilepsy, these studies would need to be repeated in a model of chronic epilepsy with spontaneous seizures, such as occurs in post-status epilepticus rat models.
Supra-additive effects observed in preclinical seizure models may not always translate to clinical efficacy, and studies of synergism for selected combinations of antiseizure drugs are not commonly used. However, it is noteworthy that in some cases potential supra-additive effects have been observed. For example, in a small group of patients receiving both ethosuximide and VPA, an enhanced effect was observed against refractory absence seizures. 39 Similarly, beneficial interactions have been observed for the combination of LTG with VPA for patients with refractory partial epilepsy. 40 Furthermore, positive pharmacodynamic interactions between lacosamide and LEV (as well as carbamazepine, LTG, topiramate, and gabapentin) have been demonstrated in the mouse 6-Hz (32-mA) seizure model, 28 and this interaction has also been observed in clinical studies. [41] [42] [43] Furthermore, in most cases, despite the finding that many antiseizure drugs can affect the metabolism of other antiseizure drugs, the combinations described above are generally without substantial pharmacokinetic interactions. 43 To our knowledge, our study reports for the first time a strong synergy for a combination of 2 anticonvulsant drug classes in the more pharmacoresistant 6-Hz 44-mA assay. Further synergistic efficacy was observed without any negative interaction in the rotarod assay. Moreover, the extent of synergy as shown in the isobolographic approach has not been reported before in this model. Assuming that this synergistic combination of mGlu 2 PAMs with LEV translates into a clinically meaningful effect, the combination of an mGlu 2 PAM and LEV might constitute a true rational polypharmacy therapy for patients with refractory seizures. 
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